Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway

  • Authors:
    • Canguang Jin
    • Zhikang Chen
    • Wei Shi
    • Qi Lian
  • View Affiliations

  • Published online on: March 7, 2019     https://doi.org/10.3892/or.2019.7052
  • Pages: 3060-3068
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tropomodulin 3 (TMOD3) is a member of the pointed‑end capping protein family that contributes to invasion and metastasis in several types of malignancies. TMOD3 has been found to be crucial for membranous skeleton and embryonic development; however, little is known regarding the role of TMOD3 in liver cancer progression. In addition, to the best of our knowledge, no previous studies have investigated the mechanism underlying the TMOD3‑regulated promotion of liver cancer. The aim of the present study was to determine whether TMOD3 is associated with liver cancer progression. TMOD3 expression was found to be elevated in liver cancer cells and tissues. In the in vitro experiments, liver cancer cell proliferation, invasion and migration were inhibited by TMOD3 knockdown and promoted by ectopic expression of TMOD3. Furthermore, mechanistic analysis indicated that TMOD3 overexpression activated mitogen‑activated protein kinase (MAPK)/extracellular signal‑regulated kinase (ERK) signaling and increased the levels of other targets of this pathway, including matrix metalloproteinase (MMP)2, MMP9 and cyclin D1. TMOD3 overexpression was associated with changes in liver cancer cell morphology and altered expression of epithelial and mesenchymal markers. High TMOD3 expression was hypothesized to promote epithelial‑to‑mesenchymal transition in liver cancer cells. In conclusion, TMOD3 was shown to promote liver cancer cell growth, invasion and migration through the MAPK/ERK signaling pathway, and it may serve as a candidate biomarker and therapeutic target in liver cancer.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Forner A, Reig M and Bruix J: Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Fu J, Li Y, Li Z and Li N: Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinoma. Biosci Rep. 38:BSR201800442018. View Article : Google Scholar : PubMed/NCBI

4 

El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK and Are C: A Review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 263:1112–1125. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Weber A, Pennise CR, Babcock GG and Fowler VM: Tropomodulin caps the pointed ends of actin filaments. J Cell Biol. 127:1627–1635. 1994. View Article : Google Scholar : PubMed/NCBI

7 

Narita A, Oda T and Maéda Y: Structural basis for the slow dynamics of the actin filament pointed end. EMBO J. 30:1230–1237. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Fischer RS and Fowler VM: Tropomodulins: Life at the slow end. Trends Cell Biol. 13:593–601. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Weber KL, Fischer RS and Fowler VM: Tmod3 regulates polarized epithelial cell morphology. J Cell Sci. 120:3625–3632. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Lim CY, Bi X, Wu D, Kim JB, Gunning PW, Hong W and Han W: Tropomodulin3 is a novel Akt2 effector regulating insulin-stimulated GLUT4 exocytosis through cortical actin remodeling. Nat Commun. 6:59512015. View Article : Google Scholar : PubMed/NCBI

11 

Yamashiro S, Gokhin DS, Kimura S, Nowak RB and Fowler VM: Tropomodulins: Pointed-end capping proteins that regulate actin filament architecture in diverse cell types. Cytoskeleton. 69:337–370. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Cox-Paulson EA, Walck-Shannon E, Lynch AM, Yamashiro S, Zaidel-Bar R, Eno CC, Ono S and Hardin J: Tropomodulin protects α-catenin-dependent junctional-actin networks under stress during epithelial morphogenesis. Curr Biol. 22:1500–1505. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Moyer JD, Nowak RB, Kim NE, Larkin SK, Peters LL, Hartwig J, Kuypers FA and Fowler VM: Tropomodulin 1-null mice have a mild spherocytic elliptocytosis with appearance of tropomodulin 3 in red blood cells and disruption of the membrane skeleton. Blood. 116:2590–2599. 2010. View Article : Google Scholar : PubMed/NCBI

14 

Sui Z, Nowak RB, Sanada C, Halene S, Krause DS and Fowler VM: Regulation of actin polymerization by tropomodulin-3 controls megakaryocyte actin organization and platelet biogenesis. Blood. 126:520–530. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Sui Z, Nowak RB, Bacconi A, Kim NE, Liu H, Li J, Wickrema A, An XL and Fowler VM: Tropomodulin3-null mice are embryonic lethal with anemia due to impaired erythroid terminal differentiation in the fetal liver. Blood. 123:758–767. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Sun Y, Liu WZ, Liu T, Feng X, Yang N and Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Cox PR and Zoghbi HY: Sequencing, expression analysis, and mapping of three unique human tropomodulin genes and their mouse orthologs. Genomics. 63:97–107. 2000. View Article : Google Scholar : PubMed/NCBI

18 

Fischer RS, Yarmola EG, Weber KL, Speicher KD, Speicher DW, Bubb MR and Fowler VM: Tropomodulin 3 binds to actin monomers. J Biol Chem. 281:36454–36465. 2006. View Article : Google Scholar : PubMed/NCBI

19 

Pollard TD and Cooper JA: Actin, a central player in cell shape and movement. Science. 326:1208–1212. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Diz-Muñoz A, Fletcher DA and Weiner OD: Use the force: Membrane tension as an organizer of cell shape and motility. Trends Cell Biol. 23:47–53. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Jo YJ, Jang WI, Kim NH and Namgoong S: Tropomodulin-3 is essential in asymmetric division during mouse oocyte maturation. Sci Rep. 6:292042016. View Article : Google Scholar : PubMed/NCBI

22 

Chaigne A, Campillo C, Voituriez R, Gov NS, Sykes C, Verlhac MH and Terret ME: F-actin mechanics control spindle centring in the mouse zygote. Nat Commun. 7:102532016. View Article : Google Scholar : PubMed/NCBI

23 

Paez AV, Pallavicini C, Schuster F, Valacco MP, Giudice J, Ortiz EG, Anselmino N, Labanca E, Binaghi M, Salierno M, et al: Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer. Cell Death Dis. 7:e25702016. View Article : Google Scholar : PubMed/NCBI

24 

Pawlak G, McGarvey TW, Nguyen TB, Tomaszewski JE, Puthiyaveettil R, Malkowicz SB and Helfman DM: Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. Int J Cancer. 110:368–373. 2004. View Article : Google Scholar : PubMed/NCBI

25 

Kyriakis JM and Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update. Physiol Rev. 92:689–737. 2012. View Article : Google Scholar : PubMed/NCBI

26 

De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16 (Suppl 2):S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Liao YJ, Fang CC, Yen CH, Hsu SM, Wang CK, Huang SF, Liang YC, Lin YY, Chu YT and Arthur Chen YM: Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications. Int J Cancer. 137:1341–1351. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Chung W, Kim M, de la Monte S, Longato L, Carlson R, Slagle BL, Dong X and Wands JR: Activation of signal transduction pathways during hepatic oncogenesis. Cancer Lett. 370:1–9. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Fang Y, Liu G, Xie C, Qian K, Lei X, Liu Q, Liu G, Cao Z, Fu J, Du H, et al: Pharmacological inhibition of TRPV4 channel suppresses malignant biological behavior of hepatocellular carcinoma via modulation of ERK signaling pathway. Biomed Pharmacother. 101:910–919. 2018. View Article : Google Scholar : PubMed/NCBI

30 

Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Tashiro E, Tsuchiya A and Imoto M: Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 98:629–635. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI

33 

De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Meng L, Wang X, Liao W, Liu J, Liao Y and He Q: BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells. Oncol Rep. 38:3327–3334. 2017.PubMed/NCBI

35 

Chen JH, Zhou LY, Xu S, Zheng YL, Wan YF and Hu CP: Overexpression of lncRNA HOXA11-AS promotes cell epithelial-mesenchymal transition by repressing miR-200b in non-small cell lung cancer. Cancer Cell Int. 17:642017. View Article : Google Scholar : PubMed/NCBI

36 

Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo C, Yin L, Han Y, Cai C, Li Y, et al: BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma. Cancer Lett. 411:117–129. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May 2019
Volume 41 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jin, C., Chen, Z., Shi, W., & Lian, Q. (2019). Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway. Oncology Reports, 41, 3060-3068. https://doi.org/10.3892/or.2019.7052
MLA
Jin, C., Chen, Z., Shi, W., Lian, Q."Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway". Oncology Reports 41.5 (2019): 3060-3068.
Chicago
Jin, C., Chen, Z., Shi, W., Lian, Q."Tropomodulin 3 promotes liver cancer progression by activating the MAPK/ERK signaling pathway". Oncology Reports 41, no. 5 (2019): 3060-3068. https://doi.org/10.3892/or.2019.7052